Acneiform Skin Lesions Associated With Cetuximab Therapy: Report of Two Cases

Abstract

Cetuximab, is an IgG1 chimeric monoclonal antibody type of epidermal growth factor receptor (EGFR). It is most commonly prescribed for metastatic colorectal cancer, administered alone or in combination with irinotecan-based chemotherapy regimens (Lee et al., 2008;Segaert and Cutsem 2005;Scope et al., 2009). Acneiform eruption is the most common adverse effect with 80% of incidence (Segaert and Cutsem 2005;Lee et al., 2008). We report two cases of severe acneiform eruption induced by cetuximab with metastatic colorectal cancer.